ABSTRACT
INTRODUCTION
Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies, and the majority of these patients die as a result of metastatic disease. The phenomenon of cancer metastasis has been extensively studied and characterized as a complex, multistep process.
To produce metastatic outgrowth, tumor cells need to be pro cient in all steps of the metastatic process, including invasion, embolization, survival in the circulation, arrest in a distant capillary bed, and proliferation within the organ parenchyma. Tumor cells acquire these biological properties by the accumulation of (epi)genetic alterations. 1 One hypothesis on the acquisition of a metastatic phenotype is that these modi cations are already present in the primary tumor. This is supported by the nding that gene expression signatures of the primary tumor have been shown to predict the occurrence of metastasis in patients with breast cancer. 2 Like other types of cancer, CRC shows organ preference for metastasis formation. The liver is the predominant site in approximately 80% of patients with CRC. In 40-50% of these patients, extrahepatic organs are also involved in metastatic colonization. 3 Lung metastases develop in 5-15% of the patients, and metastases in the central nervous system, adrenal glands, ovaries, skeleton, and skin together account for <10% of all colorectal metastases. 4 Metastatic cells prefer to grow in certain organs in a way that cannot be explained by circulatory patterns alone. Organ speci city has mainly been investigated in animal models, 5, 6 but gene expression pro ling in human breast cancer tissue can predict bone and lung metastases. 7, 8 The development of DNA microarray technology, which allows for genome-wide pro ling, has provided new insight into the genetic basis of metastasis.
However, so far, neither chromosomal aberrations nor gene expression pro ling in the primary tumor have been correlated with hepatic versus extrahepatic metastasis in CRC.
CRC in many aspects, including prognosis and survival, is a heterogeneous disease.
In case of unresectable metastatic CRC, patients are treated with cytotoxic regimens ( uoropyrimidines, oxaliplatin, irinotecan) in combination with targeted therapy (vascular endothelial growth factor and epidermal growth factor receptor antibodies). There are con icting data available on the prognostic value of organ-speci c metastasis in patients treated with systemic therapy. Several studies reported the presence of liver metastases as a negative predictor, [9] [10] [11] [12] [13] [14] while others observed survival bene t in patients with hepatic metastases compared to patients with lung metastases. [15] [16] [17] So far, no studies have been performed to evaluate the differences in patients with hepatic versus extrahepatic metastases in terms of clinicopathological features and outcome.
The present study aimed to identify clinicopathological features, chromosomal aberrations and outcome associated with hepatic versus extrahepatic metastasis in patients with CRC.
MATERIALS AND METHODS

Patients
The patients included in this analysis participated in the CAIRO study (CKTO 2002-07, Clinical Trials. gov; NCT00312000) of the Dutch Colorectal Cancer Group (DCCG). 18 In this multicenter phase III trial, 820 patients with metastatic CRC without prior systemic treatment for metastatic disease were randomized between sequential and combination treatment with capecitabine, irinotecan and oxaliplatin. The primary end point of the study was overall survival (OS). The written informed consent required for all patients before study entry also included translational research on tumor tissue. For the present analysis, we selected 550 eligible patients who underwent a resection of the primary tumor, for which formalin-xed paraf n-embedded (FFPE) material of the primary tumor was available. Patients were divided according to the site of the metastases in exclusively hepatic (n=182) and exclusively extrahepatic disease (n=139). Patients with a combination of hepatic and extrahepatic metastases (n=221), locally advanced disease (n=7) and for whom the metastatic site was unknown (n=1) were excluded from this analysis.
Clinical and histopathological parameters
The following clinical features were collected for each patient: age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, serum lactate dehydrogenase (LDH), site of the primary tumor, previous adjuvant therapy, number of metastatic sites involved, metachronous (> 6 months after initial diagnosis) or synchronous (£ 6 months of initial diagnosis) onset of metastases, and regimen used as rst-line treatment.
The TNM (tumor, node, metastases) classi cation was used to describe the extent of cancer spread in terms of invasion depth and lymph node stage. 19 Histopathological review was carried out by two independent observers (LJMM, IDN). If the scoring was not unambiguous, the opinion of the pathologist (IDN) was nal. Tumors were classi ed using the WHO guidelines. 20 A tumor was considered to be of the mucinous type when at least 50% of the tumor volume consisted of mucin. Primary tumors were graded into well, moderately and poorly differentiated adenocarcinomas based on the part of poorest differentiation in the tumor. The mismatch repair system status was determined by immunohistochemistry and microsatellite instability analysis.
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Data analysis of clinicopathological features and outcome
Clinical and histopathological characteristics of patients with hepatic and extrahepatic metastases were compared using the Wilcoxon signed rank test or 2 test where appropriate. OS was calculated as the interval from the date of randomisation until death from any cause or until the date of last follow-up. Progression free survival (PFS) for rstline treatment was calculated from the date of randomisation to the rst observation of disease progression or death from any cause. OS and PFS curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Patients were considered evaluable for response if they had completed at least three cycles of chemotherapy. Overall response was de ned as partial response or complete response. Disease control was de ned by stable disease with a duration of more than 4 months or partial response or complete response. Differences in response and disease control rates were analysed by a 2 model. Multivariate analysis of OS was performed by means of a Cox proportional hazards model, including the following covariates: gender, performance status, serum LDH, site of the primary tumour, number of metastatic sites involved, T stage, N stage, classi cation and differentiation grade of the primary tumour. All statistical tests were two-sided, and p values of <0.05 were considered signi cant.
Sample selection for DNA copy number pro ling
To asses DNA copy number pro les we used an array comparative genomic hybridization In this multicenter phase III trial, patients were randomly assigned to rst-line treatment with capecitabine, oxaliplatin, and bevacizumab, or the same schedule with the addition of cetuximab. Since the CAIRO2 study had a negative outcome, possibly because of a negative interaction between the study drugs, the array CGH pro les were determined only in patients receiving capecitabine, oxaliplatin and bevacizumab. The selection criteria for the patients used for both the training and validation set are described in detail elsewhere (Haan et al. In preparation). Brie y, primary tumors were selected from patients who underwent a resection of the primary tumor and for whom FFPE material of the primary tumor was available. Since we used normal as well as tumor DNA from the same patient, FFPE material for both needed to be available. Stringent criteria were used to select patients based on tumor cell percentage (at least 70%), clinical variables (matched to the strati cation parameters in the original studies) and DNA quality (speci c activity at least 16 pmol/µg).
The clinicopathological features of patients in both the learning (Supplemental Table 1) and validation (Supplemental Table 2 ) array CGH datasets are representative for the larger dataset used for clinicopathological comparisons.
DNA isolation
DNA was isolated using an extensively validated protocol as previously described. 23 For each tumor an area was marked containing at least 70% tumor cells. Of the FFPE blocks two to six 10 μm sections were cut, deparaf nized and microdissected. DNA was extracted using a column-based method (QIAmp microkit, Qiagen, Germany). Matched normal mucosa DNA was used from all of these samples as a reference and was obtained from the resection margins or at least 1 cm distance from the tumor. Normality was con rmed in silico for each reference by comparing the array signals of the normal reference of another patient by across array. 24 All DNA concentrations were measured on a Nanodrop ND-1000 spectrophotometer (Thermo Scienti c, Wilmington, USA).
Array Comparative Genomic Hybridization
Labelling and hybridization was carried out as previously described. 24 Brie y, 500 ng genomic DNA and matched normal DNA were labelled using a CGH labelling kit for oligo arrays (Enzo Life Sciences, Farmingdale, USA) with cyanine 3-dUTP and cyanine 5-dUTP nucleotide mixture, respectively. Labelled DNA quality was tested by using the Nanodrop ND-1000 spectrophotometer (Thermo Scienti c, Wilmington, USA) to measure speci c activity. Samples with speci c activity <16 pmol/µg were considered insuf ciënt, and these cases were replaced by comparable samples. Hybridizations were performed on the Agilent 
Preprocessing aCGH data and data analysis
Array image analysis was performed using Features Extraction software (V.10.5. Wave patterns occurring in the genomic pro les were smoothed with the R package NoWaves. 25 The R package CGHcall 26 was used to preprocess and normalize the data. Cellularities were set to the cellularity determined by a pathologist and median normalization was performed. The R package DNAcopy 27 segmented the log 2 ratios and they were renormalized by mode normalization. Chromosomal copy number losses and gains were identi ed by CGHcall, calling probabilities of 0.5 or more. The accuracy of the normalization, segmentation and calling was veri ed by visual inspection. To reduce the dimension of the array CGH data set without loss of information, regions were de ned as previously described. 28 For supervised analysis a two-sample Wilcoxon test using 10.000 permutations was performed to calculate the signi cance of DNA copy number differences between patients with hepatic versus extrahepatic metastases. 29 Two separate tests were performed to compare frequencies of gains and losses between both groups. To account for multiple testing, a permutation-based false discovery rate (FDR) was applied to the p values.
Gene dosage effects
To identify genes on the relevant chromosomal regions that show a gene dosage effect (i.e.
mRNA expression levels are correlated with DNA copy number status) in CRC, a data set was used from The Cancer Genome Atlas (TCGA) Data Portal (http://tcga-data.nci.nih.
gov/tcga/) with combined mRNA and DNA copy number data. DNA copy numbers were available as segmented data, of which primary tumors with log 2 ratios lower than -0.5 were called as "loss" and values higher than 0.5 were called as "gain".
A two-sample Wilcoxon test was used to compare log 2 mRNA expression ratios between patients with and without DNA copy number gain. To account for multiple testing, a permutation-based FDR was applied to the p values.
Immunohistochemistry on tissue microarrays (TMAs)
From the FFPE primary tumour tissues available from patients with CRC in the CAIRO and CAIRO2 studies with hepatic and extrahepatic metastases, a 2 mm punch was taken to assemble TMAs. From each TMA, a 4 mm section was mounted on glass, deparaf nised and rehydrated. Endogenous peroxidase activity was blocked with 3% H2O2 for 30 min.
After microwave antigen retrieval using 10 mM sodium citrate buffer (pH 6.0), slides were incubated with rabbit antibody to human polyclonal C20Orf3 (1:800 dilution; SigmaAldrich, St Louis, Missouri, USA) overnight at 4°C. Subsequently, sections were incubated with Powervision Poly-HRP anti-Ms/Rb/Ra IgG (Immunologic, Duiven, The Netherlands) and developed using PowerDAB (Immunologic). The slides were counterstained with haematoxylin and evaluated by two independent observers (LJMM, MEVB). In the case of discrepancy, a de nite result was generated based on the expertise of a third investigator (IDN). All three investigators were blinded to the clinical and array CGH data. Stromal tissue served as a positive internal control. C20orf3 protein expression was negative if none of the tumour cells showed cytoplasmic/nuclear membrane staining, and positive if at least one tumour cell showed staining. The staining intensity was graded as negative (no staining), weak (light brown), moderate (brown) or strong (dark brown). A 2 model was used to compare protein expression between patients with hepatic versus extrahepatic metastases. Subsequently, protein expression was also correlated with the ordinal array CGH data. All statistical tests were two-sided, and differences were considered signi cant when p values were below 0.05.
RESULTS
Clinical and histopathological features associated with organ-speci c metastasis
Compared with patients with extrahepatic metastases (n=139), patients with hepatic metastases (n=182) were signi cantly more often male (p=0.002), more often had serum LDH activity above the upper limit of normal (p<0.0001), exhibited primary tumour localisation in the colon (p=0.03), showed synchronous onset of metastases (p<0.0001), and had less commonly received previous adjuvant chemotherapy (p<0.0001). There were no signi cant differences between patients with hepatic versus extrahepatic metastases in age (median 65 vs 63 years, p=0.39, respectively), performance status at randomisation (both groups 97% WHO 0-1) and treatment arm (both groups 47% sequential arm) (table 1).
Primary tumours of patients with hepatic metastases more often had T3 stage (p=0.006), and mucinous histology (p=0.02) was less often observed in patients with hepatic compared with extrahepatic metastases. No signi cant differences between patients with hepatic versus extrahepatic metastases were observed in diameter (both median 45 mm), lymph node status, differentiation grade, and mismatch repair (MMR) status (de cient MMR in 3% vs 4%, p=0.44, respectively) (table 1).
The prognostic value of organ-speci c metastases
No signi cant difference in median OS was observed for patients with hepatic versus extrahepatic metastases in univariate analysis (20.3 vs. 19.9 months, respectively; p=0.55).
The absence of a signi cant impact on prognosis was con rmed for hepatic versus extrahepatic metastases in multivariate analysis (HR 0.90; 95% CI 0.66-1.23; p=0.52).
The median PFS in rst line treatment was not signi cantly different between patients with hepatic versus extrahepatic metastases (8.2 vs. 7.0 months, respectively; p=0.46). A total of 291 patients were assessable for response in First-line treatment: 158 in the hepatic group and 133 in the extrahepatic group. The overall response rate (complete plus partial tumor response) in rst-line treatment was signi cantly better in patients with hepatic metastases than patients with extrahepatic metastases (43% vs. 27%, respectively; p=0.007). The disease control rate (complete plus partial tumor response plus stable disease) in rst-line treatment was not signi cantly different between patients with hepatic and extrahepatic metastases (85% vs. 86%, respectively; p=0.74).
Identi cation of a DNA copy number pro le associated with organ-speci c metastasis
The frequency plots of DNA copy number aberrations throughout the genome in patients with hepatic (n=85) and extrahepatic (n=54) metastases were very similar (Figure 1 ).
Despite the high concordance level between the two groups, small differences in DNA copy number pro le were observed. Patients with hepatic metastases had signi cantly more gains at 20p11 then patients with extrahepatic metastases (p<0.05; FDR = 0.88) (Supplemental Table 3 ). Loss at 5q12 was signi cantly less commonly observed in patients with hepatic versus extrahepatic metastases (p<0.05; FDR = 0.54)(Supplemental Table 4 ). To validate these differences in DNA copy number pro les, an additional independent validation set of 45 patients with hepatic metastases and 35 patients with extrahepatic metastases was selected. Signi cantly more gains at 20p11 in patients with hepatic versus extrahepatic metastases were con rmed (FDR<0.05) (Figure 1 ; Supplemental Table 5 ).
Differences in copy number aberrations at 5q12 could not be validated.
Identi cation of differentially expressed genes at 20p11
To determine the most relevant genes at 20p11 with a potential role in hepatic-speci c CRC metastasis, we used a publicly available dataset of 141 CRC patients. For these patients, both DNA copy number and gene expression pro ling of the primary tumor were available. Putative genes with a dosage effect were identi ed by comparing tumors with 20p11 gain to tumors without 20p11 gain. This approach revealed 12 out of 28 genes with expression levels that were signi cantly in uenced by the occurrence of 20p11 gain, namely XRN2, NXT1, GZF1, NAPB, CSTL1, CST3, CST5, C20orf3, ACSS1, ENTPD6, PYGB, ABHD12 (Supplemental Table 6 ). Of these 12 differentially expressed genes, C20orf3 showed the strongest correlation between copy number status and RNA expression (FDR<0.0001) (Figure 2 ). 
Con rmation of differential expression by immunohistochemistry
Using the TMAs of both CAIRO and CAIRO2 patients, C20orf3 expression could be determined in 581 patients, of which 325 had hepatic metastases and 283 extrahepatic metastases. Examples of C20orf3 expression in TMA cores of primary adenocarcinomas were shown in Figure 3 . In situ con rmation of C20orf3 protein expression yielded a higher percentage of primary tumors with presence of C20orf3 staining in patients with hepatic versus extrahepatic metastases (59% versus 41%, respectively; p=0.01)( Table   2 ). In 199 out of the 219 patients with copy number data, copy number status was correlated with C20orf3 expression. A signi cant positive correlation of C20orf3 protein expression with the ordinal array CGH ratios was shown as well (p<0.0001)( Table 3) .
Validation of other genes was hampered by the unavailability of adequate antibodies for immunohistochemistry on FFPE tissues. 
DISCUSSION
In this study we characterized speci c clinicopathological features and genomic aberrations of the primary tumor in CRC patients with hepatic versus extrahepatic metastases.
In patients with hepatic metastases, the primary tumor was more often in the colon.
The venous drainage of the colon is via the portal system, therefore the liver has always been regarded as the rst site of hematogenous spread. The increased incidence of extrahepatic metastases in rectosigmoid and rectal carcinoma can be attributed to the direct hematogenous spread into the systemic circulation via the inferior and middle rectal veins. However, over one-third of patients with colon carcinomas develop extrahepatic metastases. This supports a substantial role for features that are inherent to the cancer cell and the micro-environment. In the present study, liver-speci c metastasis was more often observed in males than female patients. This observation was also reported in a smaller cohort of patients, 30 but a clear explanation is lacking. The onset of metastases is another clinical feature associated with site-speci c metastasis. The majority of patients with stage IV disease present with hepatic metastases at diagnosis, and only one-sixth of the patients had extrahepatic metastases. These differences may partly be related to the diagnostic procedures, since extrahepatic metastases may be more dif cult to detect. Indeed, progress have been made in diagnostic techniques, which may explain the rising incidence of synchronous pulmonary metastases from CRC. 31 The third clinical feature associated with site-speci c metastasis is serum LDH. Our results con rm that this variable is not only a surrogate estimate for tumor burden, but also a serological factor for hepatic metastases. 32 Pathological examination of CRC resection specimens identi ed T stage and tumor type, which are correlated with organ-speci c metastases. T1 and T2 tumors do not often metastasize, but, if distant spread occurs, they are more likely to arrest outside the liver.
These tumors are located in the mucosa or submucosa, which have the greatest density of lymphatic vessels. 33 We hypothesize that T1 and T2 tumors metastasize via these lymphatic vessels, thereby escaping entrapment in the liver and producing outgrowth in extrahepatic organs. Mucinous adenocarcinomas are a less common histological subset of CRC, also appearing to metastasize more often in extrahepatic organs. These tumors probably possess speci c traits that stimulate invasion in extrahepatic organs, but the underlying mechanism is unknown.
Several prognostic factors have been investigated in metastatic CRC, but the in uence of metastatic site as an additional predictor for outcome is highly controversial. Despite differences in clinicopathological features between patients with hepatic and extrahepatic metastases, the median OS and PFS were not signi cantly different between the groups.
Even after correction for multiple prognostic factors, established in the same study population in a previous study, 34 metastatic site is not an independent prognostic factor for survival in CRC. However, we observed a higher overall response rate to rst-line chemotherapy in patients with hepatic metastases than in those with extrahepatic metastases. First, there may be a bias in response assessments, since liver metastasis may be easier to assess compared to extrahepatic metastases. Secondly, signi cant more patients with extrahepatic metastases were treated with previous adjuvant chemotherapy, while patients with hepatic metastases were not. This could in theory have resulted in a (partial) resistance to chemotherapy in the former group. However, the differences in overall response rates between patients with hepatic and extrahepatic metastases did not translate into differences in survival. This is in line with a previous study by our group 34 in which we established that the application of previous adjuvant chemotherapy was not of prognostic value in the same patient cohort.
Genomic aberrations responsible for CRC metastasis to the liver remain speculative and poorly understood. Most of the existing data were obtained using experimentally derived mouse tumor models. In the present study, we aimed to investigate genomic aberrations that drive CRC cells to the liver directly from human samples. The comparison of primary tumors derived from patients with hepatic and extrahepatic metastases identi ed more gains at 20p11 in patients with hepatic metastases. In contrast to 20q, the correlation of 20p11 with liver metastasis has not previously been described. Gain of 20q is a common genomic aberration in CRC and an indicator of poor prognosis 35 and metastatic potential. 36 Chromosome 20q gains are more often observed in primary tumors that metastasize to the liver compared to tumors that metastasize to the peritoneum and tumors without distant metastases. 30 The design of our study and our patient selection are different, as we exclusively used tumors that possess metastatic potential. Therefore, differences in gain of 20p11 are more likely to attribute to organ-speci c metastasis.
Next, our array contained 180880 nucleotides, and an adequate number of samples was analyzed, therefore we expect an increased power in our analysis. However, our results only suggest a correlation between 20p11 gain in the primary tumor and liver metastases.
We should keep in mind that primary tumors are highly heterogeneous in terms of both their cell populations and their ability to metastasize. Therefore, it may be that the genes responsible for organ tropism might not be detected in the bulk of the primary tumor. A next step could be to search directly for genes involved in organ-speci c metastases by pro ling metastatic samples from different secondary sites in relation to their primary tumor.
The number of genes at 20p11 is too high to really disclose genes that play a role in organspeci c metastases. Not all genes mapping at gained regions are recurrently overexpressed; therefore we compared gene expression between tumors with and without 20p11 gain.
Of the 12 out of 28 genes at 20p11 with a dosage effect on expression, C20orf3 showed the strongest correlation, and protein expression was associated with hepatic-speci c metastases. C20orf3 is a member of the lactonohydrolase super family, and the potential involvement of this protein in enzymatic processes is suggested. 37 Protein expression has mainly been demonstrated in the liver, but no relation to hepatic-speci c metastases has yet been reported. In vitro assays should provide evidence for a causal role of this gene in metastasis formation. In addition, con rmation of their relevance to liver-speci c metastasis can be made by showing functional evidence of the pro-liver-metastatic effect in a xenograft model. It is interesting that C20orf3 maps on the opposite allele at a distance of a few kilobases from the human CMAP gene, which is correlated with liver metastases. 38 However, in the publicly available dataset we used, CMAP was not overexpressed in 20p11 Endothelial adhesive interactions and certain aspects of the vasculature have been proposed to contribute to dissemination in speci c organs. 39 Some studies suggest that the secretion of cytokines results in a pro-metastatic microenvironment, 40, 41 but these data need further characterization in cancer models.
In conclusion, an array CGH pro le including the protein-encoding gene C20orf3 was overrepresented in primary CRCs that preferentially metastasize to the liver. Although selected from a large clinical trial, it should be realized that our results are derived from a retrospective analysis. Therefore selection bias cannot be excluded, and prospective studies on this topic are warranted. Furthermore, the possible role of this liver metastasisassociated gene in speci c steps of the hepatic metastatic process needs to be functionally validated. This could result in the development of (1) 
